I-Athena Bioscience, LLC ibhengeze izicwangciso zokusungulwa kwentengiso ye-Nexiclon XR, i-clonidine kuphela i-tablet ye-clonidine eyandisiweyo yokukhululwa eboniswe kunyango lwe-hypertension. Ukuqaliswa kumiselwe ku-Epreli ka-1 kuwo onke amazwe angama-2021 ase-US.
Ngokomyinge, kuphela i-50% yabantu abadala babambelela kwiyeza ezingapheliyo zesifo se-2, kwaye kwimeko yoxinzelelo lwegazi oluphezulu (BP), amanqanaba aphantsi okubambelela ahambelana nokulawulwa kwe-BP embi kunye neziphumo ezibi, kuquka i-stroke, i-myocardial infarction, ukungaphumeleli kwentliziyo, kunye ukufa.3-5 I-Nexiclon XR inikezela ngeenzuzo zeklinikhi ezifanayo ze-antihypertensive ze-clonidine yokukhululwa ngokukhawuleza kwi-tablet elula, kanye ngosuku.6
“Sikholelwa ukuba uncedo lwethebhulethi kanye yonke imihla lunokuba negalelo ekwandeni kokubambelela kwesigulana kwiirejimeni zamayeza,” utshilo uJeff Bryant, i-CEO ka-Athena. "Ukuthotyelwa okungcono kufuneka kubonelele ngeziphumo zonyango eziphuculweyo kwabo baphethwe luxinzelelo lwegazi."
"Ukuphehlelelwa kwe-Nexiclon XR kubonisa impumelelo eqhubekayo ye-Tris ezisa amayeza ahlukeneyo asekelwe kwitekhnoloji kwintengiso," utshilo umphathi weTris uKetan Mehta. "Ngenxa yerekhodi yabo eqinisekisiweyo, siyavuya kuba uAthena liqabane lethu, esungula le mveliso ibalulekileyo yentliziyo." I-Nexiclon isekwe kwi-Tris's LiquiXR® iteknoloji yokuhanjiswa kweziyobisi, ekhokelele kuphuhliso lweemveliso ezininzi zodidi lokuqala.
INTO ONOKUYITHATHA KWELI NQAKU:
- On average, only 50% of adults adhere to chronic disease medications2, and in the case of high blood pressure (BP), lower levels of adherence are associated with worse BP control and adverse outcomes, including stroke, myocardial infarction, heart failure, and death.
- “We believe the convenience of a once-daily tablet can contribute to increased patient adherence to medication regimens,”.
- The launch is set for April 2022 in all 50 U.
